Information for the public

Osimertinib (Tagrisso) is available on the NHS for treating locally advanced or metastatic, epidermal growth factor receptor (EGFR) mutation-positive, non-small-cell lung cancer (NSCLC) in adults who have not had treatment for NSCLC before.

Information and support

The NHS website may be a good place to find out more.

These organisations can give you advice and support:

You can also get support from your local Healthwatch.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3882-7


This page was last updated: 14 October 2020